GlobeNewswire🇺🇸 US
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program